ONE IN FIVE WOMEN WILL DEVELOP A PELVIC MASS1
Aspira Women’s Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXTM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.
Offering Protein Biomarker and Genetic Testing options to provide greater physician insights, facilitate early detection and optimize treatment plans.
- Over 10 years of experience in Ovarian Cancer Risk assessment and Pelvic mass management
- Cutting edge bioinformatics for analysis and data management
- Experienced in quality-focused patient care
- Laboratory Research focused on innovative discovery
Explore Our Products
OVA1plus
OVA1plus is a reflex process which performs OVA1 and OVERA, both FDA-cleared tests for women with adnexal masses. OVA1plus helps you further stratify your patient’s risk of malignancy for women with pelvic masses planned for surgery. Benefits of this enhanced test offering include; Reducing the falsely elevated rate by up to 50%, maintaining the high rate of detection (sensitivity) for ovarian cancer risk, continuing to provide confidence in low-risk results with a high negative predictive value, and increased specificity by up to 20%.
GenetiX
With a focus on women’s health, Aspira Labs® offers both comprehensive and targeted genetic testing options for Hereditary Breast and Ovarian cancer as well as Carrier Screening to help guide medical management for your patient.
Synergy Technology Transfer
Aspira Synergy allows labs to significantly reduce the time needed to implement in-house testing solutions
Developed by a team of experts, Aspira Synergy informs medical choices for women’s health with the assistance of multi-marker proteins and state-of-the-art genetic testing for both carrier screening and hereditary cancer risk.
1. Moore R, Bast, R. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers or none of the above? Journal of Clinical Oncology. 2007;25 (27).https://ascopubs.org/doi/pdf/10.1200/JCO.2007.11.9594